Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
Open accessThe DOI matches its Crossref record; 384 of the 384 references it cites were found in a registry or an index.
Abstract
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clostridium difficile is a Gram‐positive extracellular pathogen, which remains localized to the gastrointestinal tract but can cause severe toxin‐mediated gastrointestinal pathology, with a mortality rate of up to 6%. 67 , 68”
From The battle for iron in enteric infections (2020) · cites this paper as [68]
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Research works printed but not linked: 3
- Health Protection Agency, 2005, Outbreak of Clostridium difficile infection in a hospital in southeast England, CDR Wkly, 15
- Tleyjeh, 2012, Association between acid-suppression therapy and Clostridium difficile infection: a systematic review and meta-analysis, Clin Microbiol Infect, 18, 113
- Polage, 2015, Overdiagnosis of Clostridium difficile infection in the molecular test era, JAMA Intern Med, 175, 1792, 10.1001/jamainternmed.2015.4114 · DOI · Paper page
Cited by
Items 101–200 of 1,000
Minkoff, N. Z., Aslam, S., Medina, M., Tanner‐Smith, E. E., Zackular, J. P., Acra, S. A., Nicholson, M. R., & Imdad, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013871.pub2 · Cited by 205
Enzymatic Transition States and Drug Design
Schramm, V. L. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00369 · Cited by 97
Metabolomic networks connect host-microbiome processes to human Clostridioides difficile infections
Robinson, J. I., Weir, W. H., Crowley, J. R., Hink, T., Reske, K. A., Kwon, J. H., Burnham, C.-A. D., Dubberke, E. R., Mucha, P. J., & Henderson, J. P. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126905 · Cited by 88
Self-citationWinston, J. A., Rivera, A. J., Cai, J., Thanissery, R., Montgomery, S. A., Patterson, A. D., & Theriot, C. M. (2020) · Infection and Immunity · doi:10.1128/iai.00045-20 · Cited by 102
The Intestinal Microbiota and Metabolites in the Gut-Kidney-Heart Axis of Chronic Kidney Disease
Huang, Y., Xin, W., Xiong, J., Yao, M., Zhang, B., & Zhao, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837500 · Cited by 109
An ecological framework to understand the efficacy of fecal microbiota transplantation
Xiao, Y., Angulo, M. T., Lao, S., Weiss, S. T., & Liu, Y.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17180-x · Cited by 89
Zakhour, J., Haddad, S. F., Kerbage, A., Wertheim, H. F. L., Tattevin, P., Voß, A., Ünal, S., Ouédraogo, A., & Kanj, S. S. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106816 · Cited by 101
Dalton, K. R., Rock, C., Carroll, K. C., & Davis, M. F. (2020) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-020-00737-2 · Cited by 95
“difficile infection, conversely treatment with the recommended vancomycin protocol has been shown to lead to our third Grampositive pathogen of concern [16].”
BackgroundSelf-citationClostridium difficile: Diagnosis and the Consequence of Over Diagnosis
Lee, H. S., Plechot, K., Gohil, S. K., & Lê, J. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00417-7 · Cited by 102
Wolf, J., Kalocsai, K., Fortuny, C., Lazăr, Ş., Bosis, S., Korczowski, B., Petit, A., Bradford, D., Croos‐Dabrera, R., Incera, E., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1149 · Cited by 97
“2582 • cid 2020:71 (15 November) • Wolf et al metronidazole for an initial nonsevere episode or first recurrence, and vancomycin (with or without metronidazole) for an initial severe episode [12].”
BackgroundMethodInfluentialYadegar, A., Pakpour, S., Ibrahim, F. F., Nabavi-Rad, A., Cook, L., Walter, J., Seekatz, A. M., Wong, K., Monaghan, T. M., & Kao, D. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.03.019 · Cited by 85
Staley, C., Kaiser, T., Vaughn, B. P., Graiziger, C., Hamilton, M. J., Kabage, A. J., Khoruts, A., & Sadowsky, M. J. (2019) · mBio · doi:10.1128/mbio.01586-19 · Cited by 85
Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation
Fujimoto, K., Kimura, Y., Allegretti, J. R., Yamamoto, M., Zhang, Y., Katayama, K., Tremmel, G., Kawaguchi, Y., Shimohigoshi, M., Hayashi, T., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.013 · Cited by 89
Beinortas, T., Burr, N. E., Wilcox, M. H., & Subramanian, V. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30285-8 · Cited by 89
Self-citationAdvances in Fecal Microbiota Transplantation for Gut Dysbiosis‐Related Diseases
Hou, S., Yu, J., Li, Y., Zhao, D., & Zhang, Z. (2025) · Advanced Science · doi:10.1002/advs.202413197 · Cited by 117
The Importance of the Microbiome in Critically Ill Patients: Role of Nutrition
Morón, R., Gálvez, J., Colmenero, M., Anderson, P. O., Barrera, J. C., & Rodríguez‐Cabezas, M. E. (2019) · Nutrients · doi:10.3390/nu11123002 · Cited by 89
Therapies to modulate gut microbiota: Past, present and future
Gupta, A., Saha, S., & Khanna, S. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i8.777 · Cited by 94
Kazakova, S. V., Baggs, J. M., McDonald, L. C., Yi, S. H., Hatfield, K. M., Guh, A. Y., Reddy, S. C., & Jernigan, J. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz169 · Cited by 81
Self-citationAngarone, M., Snydman, D. R., & Practice, T. A. I. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13550 · Cited by 83
Gargiullo, L., CHIERICO, F. D., D’Argenio, P., & Putignani, L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01704 · Cited by 89
“As per the latest guidelines of Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA)2,3, FMT is recommended for patients with multiple recurrences of CDI when the appropriate antibiotic treatments have failed (strong recommendation, moderate quality of evidence) (…”
MethodKao, D., Wong, K., Franz, R., Cochrane, K., Sherriff, K., Chui, L., Lloyd, C., Roach, B., Bai, A. D., Petrof, E. O., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00007-8 · Cited by 81
Clostridium difficile Infection: An Epidemiology Update
Roo, A. C. D., & Regenbogen, S. E. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0040-1701229 · Cited by 95
Ghani, R., Mullish, B. H., McDonald, J. A. K., Ghazy, A., Williams, H. R. T., Brannigan, E., Mookerjee, S., Satta, G., Gilchrist, M. J., Duncan, N. D., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa948 · Cited by 83
Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection
Normington, C., Moura, I. B., Bryant, J. A., Ewin, D. J., Clark, E., Kettle, M. J., Harris, H. C., Spittal, W. D., Davis, G. L., Henn, M. R., et al. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-021-00184-w · Cited by 85
Self-citationMullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D., Colville, A., Bhala, N., Iqbal, T. H., et al. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.07.037 · Cited by 79
The role of the microbiota in the management of intensive care patients
Szychowiak, P., Villageois-Tran, K., Patrier, J., Timsit, J., & Ruppé, É. (2022) · Annals of Intensive Care · doi:10.1186/s13613-021-00976-5 · Cited by 94
“Hence, FMT is now recommended as an option in the treatment of rCDI [153, 155, 156], and to date, no data supports the use of FMT in indications other than rCDI outside the context of research [157].”
MethodBishop, E. J., & Tiruvoipati, R. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac404 · Cited by 101
Safety and Tolerability of Antimicrobial Agents in the Older Patient
Soraci, L., Cherubini, A., Paoletti, L., Filippelli, G., Luciani, F., Laganà, P., Gambuzza, M. E., Filicetti, E., Corsonello, A., & Lattanzio, F. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01019-3 · Cited by 98
Fecal Microbiota Transplantation: The Evolving Risk Landscape
Gupta, S., Mullish, B. H., & Allegretti, J. R. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001075 · Cited by 84
Woods, C. R., Bradley, J. S., Chatterjee, A., Kronman, M. P., Arnold, S. R., Robinson, J. L., Copley, L. A., Arrieta, A. C., Fowler, S. L., Harrison, C., et al. (2023) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad089 · Cited by 92
Slimings, C., & Riley, T. V. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab091 · Cited by 91
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators
Mohammadi‐Shemirani, P., Sood, T., & Paré, G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01078-8 · Cited by 82
Gerding, D. N., Cornely, O. A., Grill, S., Kracker, H., Marrast, A. C., Nord, C. E., Talbot, G. H., Buitrago, M. I., Diaconescu, I. G., de Oliveira, C. M., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30614-5 · Cited by 77
Self-citationAntimicrobial resistance in Clostridioides difficile
O’Grady, K., Knight, D. R., & Riley, T. V. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04311-5 · Cited by 77
Woodworth, M. H., Hayden, M. K., Young, V. B., & Kwon, J. H. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz288 · Cited by 80
“FMT has become an important treatment for RCDI and is included in major society guidelines including those produced by the Infectious Disease Society of America and a number of European professional societies [37, 38].”
BackgroundGut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface
Sehgal, K., & Khanna, S. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284821994736 · Cited by 80
A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea
Abad, C. L. R., & Safdar, N. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.02.010 · Cited by 91
Liu, C. S., Monaghan, T. M., Yadegar, A., Louie, T., & Kao, D. H. (2023) · Antibiotics · doi:10.3390/antibiotics12071141 · Cited by 88
“Clinical practice guidelines from the Infectious Diseases of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) recommended treating the initial CDI episode with either vancomycin or fidaxomicin, with both options being preferable to metronidazole in 2017 [83].”
BackgroundClostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy
Shirley, D.-A. T., Tornel, W., Warren, C. A., & Moonah, S. N. (2023) · PEDIATRICS · doi:10.1542/peds.2023-062307 · Cited by 93
“11,46,47 Recurrence is defined as new onset of CDI symptoms with a positive C. difficile specific laboratory test following an incident episode in the previous 2 to 8 weeks.”
BackgroundInfluentialThe Role of the Microbiome in the Etiopathogenesis of Colon Cancer
Tekle, G. E., Andreeva, N., & Garrett, W. S. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-025619 · Cited by 88
Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease
Vaughn, B. P., Rank, K. M., & Khoruts, A. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.07.026 · Cited by 70
An Overview of the Molecular Methods in the Diagnosis of Gastrointestinal Infectious Diseases
Amjad, M. (2020) · International Journal of Microbiology · doi:10.1155/2020/8135724 · Cited by 70
Clostridioides difficile phage biology and application
Heuler, J., Fortier, L., & Sun, X. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab012 · Cited by 79
A Clinical Review of Diabetic Foot Infections
Chastain, C. A., Klopfenstein, N., Serezani, C. H., & Aronoff, D. M. (2019) · Clinics in Podiatric Medicine and Surgery · doi:10.1016/j.cpm.2019.02.004 · Cited by 79
Cheng, Y., Phelps, E. L., Nemes, S., Rogers, N. A., Sagi, S. V., Bohm, M. E., El-Halabi, M. M., Allegretti, J. R., Kassam, Z., Xu, H., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.12.029 · Cited by 71
“We classified CDI into severe CDI or fulminant CDI on the basis of the IDSA guidelines.(4) We defined refractory SFCDI as patients with severe or fulminant CDI who failed to respond (progressive worsening or no significant improvement in objective clinical parameters such as leukocytosis, diarrhea, hypotension, vasopr…”
MethodIncreasing antibiotic resistance in Clostridioides difficile: A systematic review and meta-analysis
Saha, S., Kapoor, S., Tariq, R., Schuetz, A. N., Tosh, P. K., Pardi, D. S., & Khanna, S. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102072 · Cited by 72
Shen, W., Deshpande, A., Hevener, K. E., Endres, B. T., Garey, K. W., Palmer, K. L., & Hurdle, J. G. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz513 · Cited by 67
Self-citationRannikko, J., Holmberg, V., Karppelin, M., Arvola, P., Huttunen, R., Mattila, E. J., Kerttula, N., Puhto, T., Tamm, Ü., Koivula, I., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2708.210018 · Cited by 76
The impact of human vaccines on bacterial antimicrobial resistance. A review
Jansen, K. U., Gruber, W. C., Simon, R., Wassil, J., & Anderson, A. S. (2021) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01274-z · Cited by 88
Capturing the environment of the Clostridioides difficile infection cycle
Schnizlein, M. K., & Young, V. B. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00610-0 · Cited by 68
Gonzales-Luna, A. J., Carlson, T. J., & Garey, K. W. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2223345 · Cited by 71
“difficile-directed antibiotic treatment was the only management strategy supported by randomized controlled trials and recommended by clinical practice guidelines.(103) Although several new antibiotics and treatment strategies, including monoclonal antibodies, were developed in the past 15 years, none have sought to r…”
MethodSelf-citationMiles-Jay, A., Snitkin, E. S., Lin, M. Y., Shimasaki, T., Schoeny, M. E., Fukuda, C., Dangana, T. E., Moore, N. M., Sansom, S. E., Yelin, R. D., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02549-4 · Cited by 71
D'Silva, K. M., Mehta, R., Mitchell, M., Lee, T. C., Singhal, V., Wilson, M. G., & McDonald, E. G. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.01.008 · Cited by 64
Role of Probiotics, Prebiotics, and Synbiotics in the Elderly: Insights Into Their Applications
Ale, E. C., & Binetti, A. G. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.631254 · Cited by 98
Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank
Chen, J., Zaman, A., Ramakrishna, B., OpenBiome Team, & Olesen, S. W. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.622949 · Cited by 77
Ianiro, G., Bibbò, S., Porcari, S., Settanni, C. R., Giambò, F., Curta, A. R., Quaranta, G., Scaldaferri, F., Masucci, L., Sanguinetti, M., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1994834 · Cited by 71
Gut metabolites predict Clostridioides difficile recurrence
Dawkins, J. J., Allegretti, J. R., Gibson, T. E., McClure, E. L., Delaney, M. L., Bry, L., & Gerber, G. K. (2022) · Microbiome · doi:10.1186/s40168-022-01284-1 · Cited by 69
Drewes, J. L., Corona, A., Sanchez, U., Fan, Y., Hourigan, S. K., Weidner, M., Sidhu, S. D., Simner, P. J., Wang, H., Timp, W., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130848 · Cited by 64
McQuade, J. L., Ologun, G. O., Arora, R., & Wargo, J. A. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00913-y · Cited by 63
McFarland, L. V., Ship, N., Auclair, J., & Millette, M. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.04.017 · Cited by 62
From obesity through gut microbiota to cardiovascular diseases: a dangerous journey
Marzullo, P., Renzo, L. D., Pugliese, G., Siena, M. D., Barrea, L., Muscogiuri, G., Colao, A., & Savastano, S. (2020) · International Journal of Obesity Supplements · doi:10.1038/s41367-020-0017-1 · Cited by 71
The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview
Fatima, R., & Aziz, M. (2019) · Cureus · doi:10.7759/cureus.3977 · Cited by 63
The battle for iron in enteric infections
Sousa Gerós, A., Simmons, A., Drakesmith, H., Aulicino, A., & Frost, J. N. (2020) · Immunology · doi:10.1111/imm.13236 · Cited by 58
Donskey, C. J. (2019) · American Journal of Infection Control · doi:10.1016/j.ajic.2019.03.017 · Cited by 62
Martínez-Gili, L., McDonald, J. A. K., Liu, Z., Kao, D. H., Allegretti, J. R., Monaghan, T. M., Barker, G. F., Blanco, J. M., Williams, H. R. T., Holmes, E. C., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1810531 · Cited by 73
“Samples from 18 patients and 3 donors were analyzed; further details on methodology are provided in the Supplementary Material.(1)H-NMR is an ‘information-rich’ analytical technique used in metabonomics and popular for its capability to simultaneously detect many biochemical entities (host and microbial) from complex…”
BackgroundMethodKhan, M. Y., Dirweesh, A., Khurshid, T., & Siddiqui, W. J. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001243 · Cited by 61
Dieterle, M. G., Rao, K. K., & Young, V. B. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13958 · Cited by 71
Laboratory Tests for the Diagnosis of Clostridium difficile
Carroll, K. C., & Mizusawa, M. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0039-3400476 · Cited by 68
Self-citationCheng, Y., Alhaffar, D., Saha, S., Khanna, S., Bohm, M. E., Phelps, E. L., Ghabril, M., Orman, E. S., Sagi, S. V., Rogers, N. A., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.051 · Cited by 66
Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review
van Rossen, T. M., Ooijevaar, R. E., Vandenbroucke‐Grauls, C. M. J. E., Dekkers, O. M., Kuijper, E. J., Keller, J. J., & van Prehn, J. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.026 · Cited by 74
The Interaction of Microbiome and Pancreas in Acute Pancreatitis
Zhang, C., Li, G., Lu, T., Liu, L., Sui, Y., Bai, R., Li, L., & Sun, B. (2023) · Biomolecules · doi:10.3390/biom14010059 · Cited by 77
Proton pump inhibitors, adverse events and increased risk of mortality
Lanas-Gimeno, A., Hijos, G., & Lanas, Á. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1664470 · Cited by 60
Johnson, S. W., Brown, S. V., & Priest, D. H. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz966 · Cited by 65
“Current guidelines do not recommend the administration of probiotics for the prevention of CDI [10, 12].”
BackgroundSelf-citationMicrobiota transplantation: Targeting cancer treatment
Wu, X., Zhang, T., Chen, X., Ji, G., & Zhang, F. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.010 · Cited by 67
Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis
Rapoport, E. A., Baig, M., & Puli, S. R. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0695 · Cited by 89
Gut Microbiota and Clostridium difficile: What We Know and the New Frontiers
Piccioni, A., Rosa, F., Manca, F., Pignataro, G., Zanza, C., Savioli, G., Covino, M., Ojetti, V., Gasbarrini, A., Franceschi, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113323 · Cited by 70
“Recurrence is said to occur when, after treatment accompanied by a total disappearance of clinical symptoms, there is a recurrence of CDI within two to eight weeks after discontinuing therapy [27].”
BackgroundClostridioides difficile, a New “Superbug”
Markovska, R. D., Dimitrov, G. T., Gergova, R. T., & Boyanova, L. (2023) · Microorganisms · doi:10.3390/microorganisms11040845 · Cited by 65
“Endoscopic investigation can reveal specific changes in the colon endothelium (pseudomembranes and ulcers), which gives the name of the disease pseudomembranous colitis [25,27].”
BackgroundMethodInfluentialAktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline
Kucharzik, T. F., Dignass, A. U., Atreya, R. N., Bokemeyer, B., Esters, P., Herrlinger, K. R., Kannengießer, K., Kienle, P., Langhorst, J., Lügering, A., et al. (2020) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1296-3444 · Cited by 72
Alteration of gut microbiota in acute pancreatitis and associated therapeutic strategies
Zhu, Y., Mei, Q., Fu, Y., & Zeng, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111850 · Cited by 69
Circadian Rhythms, the Gut Microbiome, and Metabolic Disorders
Zhao, E. H., Tait, C., Minacapelli, C. D., Catalano, C., & Rustgi, V. K. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2021.10.008 · Cited by 68
DeFilipp, Z. M., Hohmann, E. L., Jenq, R. R., & Chen, Y. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.10.022 · Cited by 63
Time-Series Analysis of Health Care–Associated Infections in a New Hospital With All Private Rooms
McDonald, E. G., Dendukuri, N., Frenette, C. H., & Lee, T. C. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2798 · Cited by 63
Engevik, M. A., Danhof, H. A., Shrestha, R., Chang‐Graham, A. L., Hyser, J. M., Haag, A. M., Mohammad, M. A., Britton, R. A., Versalovic, J. A., Sorg, J. A., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1795388 · Cited by 66
Infectious Disease Complications in Patients with Cancer
Seo, S. K., Liu, C., & Dadwal, S. (2020) · Critical Care Clinics · doi:10.1016/j.ccc.2020.09.001 · Cited by 68
The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection
Mullish, B. H., & Allegretti, J. R. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211017725 · Cited by 61
Tougas, S., Lodha, N., Vandermeer, B., Lorenzetti, D., Tarr, P. I., Tarr, G. A. M., Chui, L., Vanderkooi, O. G., & Freedman, S. B. (2021) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2021.2328 · Cited by 65
Li, B. Y., Oh, J., Young, V. B., Rao, K. K., & Wiens, J. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz186 · Cited by 65
Mullane, K. M., Dubberke, E. R., & Practice, O. B. O. T. A. I. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13564 · Cited by 59
Self-citationGut microbiota: impacts on gastrointestinal cancer immunotherapy
Lau, H. C.-H., Sung, J. J. �., & Yu, J. Q. (2021) · Gut Microbes · doi:10.1080/19490976.2020.1869504 · Cited by 60
Guh, A. Y., Hatfield, K. M., Winston, L. G., Martin, B., Johnston, H. L., Brousseau, G., Farley, M. M., Wilson, L. E., Perlmutter, R., Phipps, E. C., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz009 · Cited by 59
“Another multisite study found a higher 30-day mortality rate among 435 toxin-positive vs 207 cytotoxigenic culture-positive-only patients (comparable to NAAT-positive only) in univariate analysis, but not after adjusting for age, disease severity, and study site [20]; the lack of a significant finding in multivariable…”
ResultSelf-citationFramework for rational donor selection in fecal microbiota transplant clinical trials
Duvallet, C., Zellmer, C., Panchal, P., Budree, S., Osman, M., & Alm, E. J. (2019) · PLOS ONE · doi:10.1371/journal.pone.0222881 · Cited by 57
Perler, B. K., Chen, B., Phelps, E. L., Allegretti, J. R., Fischer, M., Ganapini, V., Krajicek, E. J., Kumar, V., Marcus, J., Nativ, L., et al. (2020) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001281 · Cited by 60
Self-citationKhanna, S., Pardi, D. S., Jones, C. R., Shannon, W. D., Gonzalez, C., & Blount, K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1430 · Cited by 60
Du, C., Luo, Y., Walsh, S., & Grinspan, A. M. (2021) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001495 · Cited by 63
Treatment ofClostridioides (Clostridium) difficileinfection
Oksi, J., Anttila, V.-J., & Eero, M. (2019) · Annals of Medicine · doi:10.1080/07853890.2019.1701703 · Cited by 70
“The CDI is mild-to-moderate when the criteria for severe or fulminant disease are not met [10,28].”
BackgroundFecal microbiota transplantation for ulcerative colitis
Matsuoka, K. (2020) · Immunological Medicine · doi:10.1080/25785826.2020.1792040 · Cited by 63
The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection
Tawam, D., Baladi, M., Jungsuwadee, P., Earl, G. L., & Han, J. (2021) · INNOVATIONS in pharmacy · doi:10.24926/iip.v12i1.3439 · Cited by 69
Olaitan, A. O., Dureja, C., Youngblom, M. A., Topf, M. A., Shen, W., Gonzales-Luna, A. J., Deshpande, A., Hevener, K. E., Freeman, J., Wilcox, M. H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39429-x · Cited by 61
Self-citationRajasingham, R., Enns, E. A., Khoruts, A., & Vaughn, B. P. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz318 · Cited by 62
Kitchin, N. R. E., Remich, S. A., Peterson, J., Peng, Y., Gruber, W. C., Jansen, K. U., Pride, M. W., Anderson, A. S., Knirsch, C. A., & Webber, C. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz153 · Cited by 60
Metadata
- Authors
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Edward Hines, Jr. VA Hospital (US)
- Loyola University Medical Center (US)
- St. Luke's Hospital (US)
- Johns Hopkins University (US)
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- University of Houston (US)
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- McGill University Health Centre (CA)
- Children’s Hospital of Philadelphia, Pennsylvania
- Boston Children's Hospital (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- McDonald, L Clifford
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-15
- Volume
- 66
- Issue
- 7
- Pages
- e1-e48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6018983
- OpenAlex
- W2791326569
- Cited by
- 2,690
- References
- 383
- Citations by year
- 2026: 148 · 2025: 179 · 2024: 215 · 2023: 305 · 2022: 331 · 2021: 423 · 2020: 486 · 2019: 408 · 2018: 185
- FWCI
- 228.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Agency for Health Research and Quality
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile infection, nosocomial infections, healthcare-associated diarrhea, pediatric infection, diagnosis, treatment, infection control, environmental management, ribotype 027, community-acquired infections, epidemiology
- MeSH terms
- Adult, Child, Clostridium Infections, Diarrhea, Humans, Retrospective Studies, Societies, Societies, Medical, Clostridioides difficile, Infectious Disease Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.